Logo image of ALNY

ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Overview

USA - NASDAQ:ALNY - US02043Q1076 - Common Stock

449.56 USD
-32.03 (-6.65%)
Last: 10/30/2025, 8:00:01 PM
449.56 USD
0 (0%)
After Hours: 10/30/2025, 8:00:01 PM

ALNY Key Statistics, Chart & Performance

Key Statistics
Market Cap58.93B
Revenue(TTM)2.46B
Net Income(TTM)-319089000
Shares131.08M
Float125.73M
52 Week High495.55
52 Week Low205.87
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.47
PEN/A
Fwd PE78.09
Earnings (Next)10-30 2025-10-30/bmo
IPO2004-05-28
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ALNY short term performance overview.The bars show the price performance of ALNY in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

ALNY long term performance overview.The bars show the price performance of ALNY in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of ALNY is 449.56 USD. In the past month the price decreased by -2.48%. In the past year, price increased by 64.13%.

ALNYLAM PHARMACEUTICALS INC / ALNY Daily stock chart

ALNY Latest News, Press Relases and Analysis

ALNY Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.55 403.13B
AMGN AMGEN INC 13.39 157.20B
GILD GILEAD SCIENCES INC 15.3 146.96B
VRTX VERTEX PHARMACEUTICALS INC 24.79 107.66B
REGN REGENERON PHARMACEUTICALS 14.53 69.32B
ARGX ARGENX SE - ADR 89.07 50.51B
INSM INSMED INC N/A 41.05B
ONC BEONE MEDICINES LTD-ADR 4.96 33.85B
NTRA NATERA INC N/A 26.52B
BNTX BIONTECH SE-ADR N/A 25.16B
BIIB BIOGEN INC 9.34 21.93B
UTHR UNITED THERAPEUTICS CORP 17.19 20.51B

About ALNY

Company Profile

ALNY logo image Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.

Company Info

ALNYLAM PHARMACEUTICALS INC

675 W Kendall St

Cambridge MASSACHUSETTS 02142 US

CEO: John M. Maraganore

Employees: 2230

ALNY Company Website

ALNY Investor Relations

Phone: 16175518200

ALNYLAM PHARMACEUTICALS INC / ALNY FAQ

Can you describe the business of ALNYLAM PHARMACEUTICALS INC?

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.


What is the stock price of ALNYLAM PHARMACEUTICALS INC today?

The current stock price of ALNY is 449.56 USD. The price decreased by -6.65% in the last trading session.


Does ALNYLAM PHARMACEUTICALS INC pay dividends?

ALNY does not pay a dividend.


What is the ChartMill rating of ALNYLAM PHARMACEUTICALS INC stock?

ALNY has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


How is the valuation of ALNYLAM PHARMACEUTICALS INC (ALNY) based on its PE ratio?

ALNYLAM PHARMACEUTICALS INC (ALNY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.47).


Can you provide the growth outlook for ALNYLAM PHARMACEUTICALS INC?

The Revenue of ALNYLAM PHARMACEUTICALS INC (ALNY) is expected to grow by 57.74% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the market cap for ALNYLAM PHARMACEUTICALS INC?

ALNYLAM PHARMACEUTICALS INC (ALNY) has a market capitalization of 58.93B USD. This makes ALNY a Large Cap stock.


ALNY Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to ALNY. When comparing the yearly performance of all stocks, ALNY is one of the better performing stocks in the market, outperforming 88.57% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ALNY Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ALNY. The financial health of ALNY is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALNY Financial Highlights

Over the last trailing twelve months ALNY reported a non-GAAP Earnings per Share(EPS) of -2.47. The EPS decreased by -311.67% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -6.99%
ROE -127.33%
Debt/Equity 4.1
Chartmill High Growth Momentum
EPS Q2Q%-292.31%
Sales Q2Q%17.26%
EPS 1Y (TTM)-311.67%
Revenue 1Y (TTM)5.02%

ALNY Forecast & Estimates

36 analysts have analysed ALNY and the average price target is 458.7 USD. This implies a price increase of 2.03% is expected in the next year compared to the current price of 449.56.

For the next year, analysts expect an EPS growth of 164.21% and a revenue growth 57.74% for ALNY


Analysts
Analysts80
Price Target458.7 (2.03%)
EPS Next Y164.21%
Revenue Next Year57.74%

ALNY Ownership

Ownership
Inst Owners98.86%
Ins Owners0.2%
Short Float %3.18%
Short Ratio3.68